Calidi Biotherapeutics, Inc.

AMEX: CLDI · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001855485Reports USD

#1085 of 1,418 Healthcare companies by revenue

EA Score

19D

FH 16DQ 20GM —SS 29

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, workforce scale · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$19.9M

Employees

as of 2026-08-26

Market cap

$603.2k

as of 2026-08-26

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$45.0k$45.0k2023

Net income-$19.9M-$19.9M2025

Operating income-$20.2M-$20.2M2025

Total assets$8.9M$8.9M2025

Liabilities$5.1M$5.1M2025

Equity$3.8M$3.8M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Calidi Biotherapeutics, Inc.’s revenue?

Calidi Biotherapeutics, Inc. booked $45.0k in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -44235.6% net margin.

Peers · Healthcare

MultiCell Technologies, Inc.——Ovation Science Inc.23D DIAGNOS Inc.29D Millennium Sustainable Ventures Corp.——Altimmune, Inc.55C Neonc Technologies Holdings, Inc.10D

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B60C Sempra$12.4B64C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+

Key facts

CEOEric E. Poma

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeAMEX: CLDI

Employees29

IPO date2021-11-01

Latest filings

10-Q2026-08-13 8-K2026-08-13 8-K2026-07-31 8-K2026-07-16 8-K2026-06-23 8-K2026-06-18 8-K2026-05-29 10-Q2026-05-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.